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Microbicides: Woman-centered HIV Prevention
Products to Help End AIDS by 2030
Invest in microbicide R&D for women—it’s the smart choice
What are microbicides?

Women bear the burden of the HIV/AIDS epidemic

Vaginal microbicides are
biomedical products being
developed to protect women
from HIV during vaginal
sex. They could come in
different forms—such as a
long-acting vaginal ring found
to help reduce HIV risk
in large clinical trials—and
other products in earlier
stages of development such
as films and inserts.

• Women and girls lack the range of prevention options they need to
protect their own health.
• HIV/AIDS is one of the leading causes of death globally in women ages
15-49, and one of the biggest threats to women’s health and well-being.
• Every day, more than 1,800 women acquire HIV, putting their sexual
and reproductive health at risk.
• Young women ages 15-24 are at greater risk. Worldwide they are
more than twice as likely to be living with HIV as young men and,
in sub-Saharan Africa, are three times as likely to acquire HIV.
• Women urgently need new HIV prevention methods like microbicides
that they can control themselves to help them protect their sexual and
reproductive health.

Small investment, enormous pay-off
• Modeling studies show that a microbicide like
a monthly vaginal ring could have a meaningful
impact on the HIV/AIDS epidemic as part of a
combination prevention strategy while helping
to empower women and girls to safeguard their
health.
• In 2020, the European Medicines Agency issued
a positive opinion for the product, and in 2021,
the World Health Organization recommended
the ring in its updated HIV prevention guidelines.
To save lives and see years of global investment
and scientific progress pay off, we must sustain
investment in microbicides.

Microbicide
R&D is a tiny
fraction—about
0.1%—of annual
development
budgets globally

0.1%

IPM is a nonprofit organization dedicated to developing new HIV prevention
technologies designed to empower women to protect their sexual and
reproductive health, and making them available in developing countries.
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The dapivirine ring—hope for women’s HIV prevention
• The monthly microbicide vaginal ring—developed by the nonprofit
International Partnership for Microbicides (IPM) with investment
from the United States and many European governments—is the
first long-acting HIV prevention method designed specifically
for women.
• The flexible silicone ring, which women insert into the vagina
themselves, is designed to slowly release the antiretroviral
drug dapivirine over the course of a month.
• The ring would help fill a critical gap in the prevention portfolio and offer
women a monthly option they can control themselves when they are
unable or choose not to use higher-efficacy products like daily oral PrEP
or a future injectable. Women need different options so they can choose
the most effective product that best meets their individual needs and
circumstances. No product is perfect, so offering a range of products
is important to ensure every woman has a way to protect herself.

Prevention is
critical
With 1.5 million new
adult infections in 2020,
treatment is essential
but cannot end the AIDS
epidemic on its own.

“Simply put, girls and women are the keys that will
unlock sustainable development. They are also
at the center of the healthier and more resilient
societies we desire.”
– Tedros Adhanom Ghebreyesus
Director-General, World Health Organization

Advancing the dapivirine ring: Status and next steps
The ring was approved in Zimbabwe and several other countries in Africa
in 2021, with additional reviews underway in eastern and southern Africa,
where HIV incidence among women is persistently high and they urgently
need new HIV prevention methods.
Where approved, the product’s introduction will be crucial to launching
follow-on products like IPM’s three-month dapivirine-contraceptive ring,
which could offer greater convenience and be appealing to women.
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Why are women at such
high risk?
Gender inequities play a major
role in limiting women’s ability
to negotiate safe sex, or even
select their partners or the
timing of sex. Women are also
biologically more susceptible
to HIV infection than men.

A Smart
investment
Investment in
woman-centered HIV
prevention promises to
yield significant economic
benefits in two key ways:

Drive economic growth
by ensuring women
are healthy enough to
work and invest in their
families’ well-being.

Investing in microbicides is smart for economic growth,
political stability and gender equality
Current HIV prevention options aren’t enough to end the epidemic.
Between 2015 and 2020, 3.5 million more infections occurred than if
UNAIDS targets had been met—including three times higher than the
target for young women.
• UNAIDS’ Global AIDS Strategy 2021-2026 explicitly recognizes the
potential for new HIV prevention tools, including ARV-based vaginal rings,
to offer women more options so they can make informed choices about
their sexual and reproductive health.
• Each dollar invested in ending the HIV/AIDS epidemic by 2030
could generate US$6.44 in economic returns in low- and middleincome countries, according to a 2019 analysis.
• Economic growth would decrease poverty, help maintain
political stability and decrease dependence on foreign aid.
• Countries that received PEPFAR assistance saw political instability
and violence fall by 40% over 10 years (2004–2014) compared to a 3%
drop in similar countries that did not.
• Microbicide R&D builds research capacity and infrastructure in areas
most affected by the epidemic, strengthening health systems.

Bring down the global cost
of AIDS treatment through
HIV infections averted.

• Microbicides would help lower HIV infection rates among women,
allowing them to pursue work and support their families, and enabling
more girls to stay in school.

Access to the ring
We are now preparing the
dapivirine ring for potential
market introduction to help
ensure it will be affordable
and accessible if it is approved
for use. Access to potentially
lifesaving new technologies
depends on sustained and
new funding.
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Investment in microbicides like the dapivirine ring
are leveraged by generous global financial support

Country governments

Philanthropic sector

Private sector

Germany
Ireland
Intellectual property, technical assistance
and support for product introduction

Netherlands
United Kingdom
United States

The contents of this document are the responsibility of IPM and do not necessarily reflect the views of its donors.

As a nonprofit product development partnership (PDP), IPM leverages
resources from public and private sectors to develop women-centered HIV
prevention technologies for use in developing countries, where the need is
urgent but market incentive is lacking.
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